PepGen Inc. (PEPG)
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
PepGen Inc.
NASDAQ:PEPGHealthcare · Biotechnology
-2.07%$2.36
AH$2.41+2.12%vs close
Mkt Cap$163.45M
Float49.09M
O/S69.26M
Vol
$ Vol
RVOL
Inst Own75.2%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$89.66M
Total Assets$173.91M
Free Cash Flow-$81.9M
Debt & Equity
Debt 10%
Equity 90%
Total Debt$17M
Total Equity$147.44M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in PEPG's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$173.91M
Liabilities$26.46M
Accounts Receivable$0
Accounts Payable$822K
Inventory$0
PP&E (Net)$21.02M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - |
| Cost of Revenue | $1.4M | $1.5M | $1.18M | $0 | $0 | $0 | $106K |
| Gross Profit | -$1.4M | -$1.5M | -$1.18M | $0 | $0 | $0 | -$106K |
| Gross Margin | - | - | - | - | - | - | - |
| Research and Development | $71.04M | $76.48M | $68.13M | $54.08M | $23.8M | $1.12M | $620K |
| Selling, General, and Administrative | $22.57M | $21.26M | $16.64M | $14.22M | $8.11M | $853K | $628K |
| Other | -$1.4M | -$1.5M | -$1.18M | $0 | -$4.8M | -$100K | $0 |
| Total Operating Expenses | $92.22M | $96.23M | $83.58M | $68.3M | $27.11M | $1.88M | $1.25M |
| Operating Income (EBIT) | -$93.61M | -$97.74M | -$84.77M | -$68.3M | -$27.11M | -$1.88M | -$1.35M |
| Operating Margin | - | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $4.02M | $7.14M | $6.4M | $2.79M | $0 | $8K | $6K |
| Other Income (Expense) | $4.01M | $7.14M | $6.21M | $2.9M | -$172K | -$12K | $8K |
| Income Before Tax (EBT) | -$89.61M | -$90.6M | -$78.55M | -$65.4M | -$27.28M | -$1.89M | -$1.35M |
| Income Tax Expense | $49K | -$617K | $73K | $3.71M | $0 | $0 | $0 |
| Net Income | -$89.66M | -$89.98M | -$78.63M | -$69.1M | -$27.28M | -$1.89M | -$1.35M |
| Net Income Margin | - | - | - | - | - | - | - |
| Supplementary Data | |||||||
| EPS | -2.12 | -2.85 | -3.30 | -4.42 | -1.22 | -0.53 | -0.06 |
| Diluted EPS | -2.12 | -2.85 | -3.30 | -4.42 | -1.22 | -0.18 | -0.06 |
| Weighted Average OS | 42.22M | 31.58M | 23.80M | 15.64M | 22.39M | 7.72M | 22.39M |
| EBITDA | -$88.21M | -$89.09M | -$77.37M | -$64.91M | -$27.1M | -$1.77M | -$1.25M |
| EBITDA Margin | - | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $60.51M | $49.42M | $80.77M | $181.75M | $132.9M | $9.78M | $3.49M |
| Short-Term Investments | $87.94M | $70.77M | $29.63M | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $148.46M | $120.19M | $110.41M | $181.75M | $132.9M | $9.78M | $3.49M |
| Accounts Receivable | $0 | $0 | $0 | $58K | $4.74M | $407K | $230K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $2.51M | $3.57M | $2.27M | $4.27M | $0 | $0 | $0 |
| Total Current Assets | $150.96M | $123.76M | $112.68M | $186.08M | $139.99M | $10.32M | $3.77M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $21.02M | $25.15M | $28.38M | $29.88M | $636K | $323K | $419K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $1.47M | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $1.92M | $1.97M | $1.99M | $1.47M | $1.55M | $0 | $0 |
| Total Long-Term Assets | $22.94M | $27.12M | $30.37M | $31.36M | $3.65M | $323K | $419K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $173.91M | $150.88M | $143.05M | $217.44M | $143.64M | $10.64M | $4.19M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $822K | $1.75M | $1M | $1.36M | $3.24M | $721K | $141K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $2.57M | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $4.66M | $3.62M | $2.37M | $2.44M | $1.21M | $28K | $0 |
| Total Current Liabilities | $12.65M | $16.7M | $17.53M | $18.83M | $10.32M | $838K | $326K |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $13.82M | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $226K | $30K | $0 |
| Total Long-Term Liabilities | $13.82M | $15.57M | $17.1M | $18.98M | $226K | $30K | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $26.46M | $32.26M | $34.63M | $37.81M | $10.55M | $868K | $326K |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $165.18M | $16.13M | $0 |
| Common Stock | $7K | $3K | $2K | $2K | $0 | $0 | $0 |
| Retained Earnings | -$361.12M | -$271.46M | -$181.48M | -$102.86M | -$33.75M | -$6.47M | -$2.39M |
| Comprehensive Income & Other | $11K | $23K | $34K | -$81K | $17K | -$8K | -$8K |
| Other Stockholders' Equity | $508.56M | $390.08M | $289.9M | $282.49M | $166.85M | $16.25M | $6.26M |
| Total Equity | $147.44M | $118.62M | $108.42M | $179.63M | $133.09M | $9.77M | $3.87M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $173.91M | $150.88M | $143.05M | $217.44M | $143.64M | $10.64M | $4.19M |
| Supplementary Data | |||||||
| Total Debt | $17M | $18.66M | $20.1M | $24.53M | $0 | $0 | $0 |
| Net Debt | -$43.51M | -$30.76M | -$60.67M | -$157.22M | -$132.9M | -$9.78M | -$3.49M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$89.66M | -$89.98M | -$78.63M | -$69.1M | -$27.28M | -$1.89M | -$1.35M |
| Depreciation & Amortization | $1.4M | $1.5M | $1.18M | $493K | $178K | $110K | $106K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $10.61M | $11.46M | $7.05M | $4.76M | $1.53M | $119K | $0 |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $0 | $0 | $26K | $4.18M | -$4.34M | -$170K | -$112K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$935K | $722K | -$369K | -$1.41M | $2.51M | $331K | $59K |
| Other Working Capital | -$5.29M | -$5.97M | $2.29M | $1.73M | $4.61M | -$153K | $349K |
| Total Working Capital Change | -$6.22M | -$5.25M | $1.95M | $4.51M | $2.77M | $8K | $296K |
| Other Non-Cash Items | $2.24M | -$107K | -$554K | $76K | $196K | $0 | $59K |
| Net Cash from Operating | -$81.64M | -$82.37M | -$69M | -$59.27M | -$22.6M | -$1.65M | -$885K |
| Investing Activities | |||||||
| Capital Expenditures | -$264K | -$497K | -$2.6M | -$3.75M | -$500K | -$8K | -$29K |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$93.97M | -$145.17M | -$29.4M | $0 | $0 | $0 | $0 |
| Sales of Investments | $79M | $108M | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$15.23M | -$37.67M | -$32M | -$3.75M | -$500K | -$8K | -$29K |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | - | - | - | - |
| Common Stock Issuance | $108.39M | $89.26M | $253K | $114.27M | $0 | $0 | $2.79M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$413K | -$511K | -$442K | -$2.07M | -$1.39M | -$3K | $0 |
| Net Cash from Financing | $107.98M | $88.75M | -$189K | $112.19M | $147.66M | $7.95M | $2.79M |
| Forex Effect | -$16K | -$62K | $286K | -$316K | $33K | -$5K | $62 |
| Net Change in Cash | $11.09M | -$31.35M | -$100.9M | $48.86M | $124.59M | $6.29M | $1.88M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$81.64M | -$82.37M | -$69M | -$59.27M | -$22.6M | -$1.65M | -$885K |
| Capital Expenditure | -$264K | -$497K | -$2.6M | -$3.75M | -$500K | -$8K | -$29K |
| Free Cash Flow | -$81.9M | -$82.87M | -$71.6M | -$63.02M | -$23.1M | -$1.66M | -$914K |
| Cash at Beginning | $50.97M | $82.32M | $183.22M | $134.37M | $9.78M | $3.49M | $1.61M |
| Cash at End | $62.06M | $50.97M | $82.32M | $183.22M | $134.37M | $9.78M | $3.49M |